Anal intraepithelial neoplasia and squamous cell carcinoma in HIV-infected adults

HIV Medicine

Volumn 15, Issue 2, 2014, Pages 65-76

  Tong, W W Y ^a   Hillman, R J ^a,c   Kelleher, A D ^a,b   Grulich, A E ^b   Carr, A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anal canal; Anal cancer; HIV; Human papillomavirus; Intraepithelial neoplasia

Indexed keywords

FLUOROURACIL; IMIQUIMOD; TRICHLOROACETIC ACID;

ANUS CANCER; ANUS CARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; VACCINATION; WART VIRUS;

ANAL CANAL; ANAL CANCER; HIV; HUMAN PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA;

ANUS NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; HIV INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS;

EID: 84891835716     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12080     Document Type: Review

References (113)

1. Silverberg MJ, Lau B, Justice AC etal. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 1026-1034.
2. Wu X, Watson M, Wilson R, Saraiya M, Cleveland JL, Markowitz L. Human papillomavirus-associated cancers - United States, 2004-2008. MMWR 2012; 61: 258-261.
3. van Leeuwen MT, Vajdic CM, Middleton MG etal. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 2009; 23: 2183-2190.
4. Darragh TM, Colgan TJ, Cox JT etal. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the college of American pathologists and the American society for colposcopy and cervical pathology. J Low Genit Tract Dis 2012; 16: 205-242.
5. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-54.
6. Bernard HU, Burk RD, Chen Z, van Doorslaer K. Hausen H and de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401: 70-79.
7. IARC. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 52.
8. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 (Suppl 1): S7-15.
9. Munoz N, Bosch FX, de Sanjose S etal. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
10. Abramowitz L, Jacquard AC, Jaroud F etal. Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2010; 129: 433-439.
11. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-2383.
12. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010; 7: 244-252.
13. Machalek DA, Poynten M, Jin F etal. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13: 487-500.
14. Kojic EM, Cu-Uvin S, Conley L etal. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011; 38: 253-259.
15. de Pokomandy A, Rouleau D, Ghattas G etal. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis 2009; 199: 965-973.
16. Vajdic CM, van Leeuwen MT, Jin F etal. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sex Transm Infect 2009; 85: 330-335.
17. Guimaraes MD, Grinsztejn B, Melo VH etal. Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil. J Acquir Immune Defic Syndr 2011; 57 (Suppl 3): S217-S224.
18. Xi LF, Critchlow CW, Wheeler CM etal. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 1998; 58: 3839-3844.
19. Goncalves MA, Randi G, Arslan A etal. HPV type infection in different anogenital sites among HIV-positive Brazilian women. Infect Agent Cancer 2008; 3: 5.
20. Piketty C, Darragh TM, Da Costa M etal. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: 453-459.
21. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183: 383-391.
22. Poynten IM, Grulich AE, Templeton DJ. Sexually transmitted infections in older populations. Curr Opin Infect Dis 2013; 26: 80-85.
23. Baranoski AS, Tandon R, Weinberg J, Huang FF, Stier EA. Risk factors for abnormal anal cytology over time in HIV-infected women. Am J Obstet Gynecol 2012; 207: 107e1-1078.
24. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012; 130: 1168-1173.
25. Jin F, Stein AN, Conway EL etal. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011; 29: 2322-2327.
26. Frisch M, Melbye M, Moller H. Trends in incidence of anal cancer in Denmark. BMJ 1993; 306: 419-422.
27. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.
28. D'Souza G, Wiley DJ, Li X etal. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491-499.
29. Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R. Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol 2011; 117: 643-649.
30. Piketty C, Selinger-Leneman H, Grabar S etal. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22: 1203-1211.
31. Seaberg EC, Wiley D, Martinez-Maza O etal. Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010; 116: 5507-5516.
32. McCredie MR, Sharples KJ, Paul C etal. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-434.
33. de Pokomandy A, Rouleau D, Ghattas G etal. HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV. Clin Infect Dis 2011; 52: 1174-1181.
34. Frazer IH, Leggatt GR, Mattarollo SR. Prevention and treatment of papillomavirus-related cancers through immunization. Annu Rev Immunol 2011; 29: 111-138.
35. Thomas MK, Pitot HC. Liem A and Lambert PF. Dominant role of HPV16 E7 in anal carcinogenesis. Virology 2011; 421: 114-118.
36. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79-82.
37. Fera D, Schultz DC, Hodawadekar S etal. Identification and Characterization of Small Molecule Antagonists of pRb Inactivation by Viral Oncoproteins. Chem Biol 2012; 19: 518-528.
38. Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene 2007; 26: 1650-1655.
39. Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 2010; 10: 699-711.
40. Kreuter A, Skrygan M, Gambichler T etal. Human papillomavirus-associated induction of human beta-defensins in anal intraepithelial neoplasia. Br J Dermatol 2009; 160: 1197-1205.
41. Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer 2010; 5: 19.
42. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002; 277: 21730-21739.
43. Lee SJ, Cho YS, Cho MC etal. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001; 167: 497-504.
44. Hasan UA, Bates E, Takeshita F etal. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-3197.
45. Karim R, Meyers C, Backendorf C etal. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 2011; 6: e17848.
46. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593-4599.
47. Carter JJ, Koutsky LA, Hughes JP etal. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-1919.
48. Lu B, Viscidi RP, Wu Y etal. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev 2012; 21: 1542-1546.
49. Viscidi RP, Ahdieh-Grant L, Clayman B etal. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003; 187: 194-205.
50. Namujju PB, Waterboer T, Banura C etal. Risk of seropositivity to multiple oncogenic human papillomavirus types among human immunodeficiency virus-positive and -negative Ugandan women. J Gen Virol 2011; 92: 2776-2783.
51. Silverberg MJ, Schneider MF, Silver B etal. Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol 2006; 13: 511-519.
52. Onda T, Carter JJ, Koutsky LA etal. Characterization of IgA response among women with incident HPV 16 infection. Virology 2003; 312: 213-221.
53. Petter A, Heim K, Guger M etal. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 2000; 81: 701-708.
54. Viscidi RP, Ahdieh-Grant L, Schneider MF etal. Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2003; 188: 1834-1844.
55. Marais DJ, Vardas E, Ramjee G etal. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions. J Infect Dis 2000; 182: 1239-1242.
56. Marais DJ, Carrara H, Ramjee G, Kay P, Williamson AL. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers. J Med Virol 2009; 81: 203-210.
57. Jain S, Moore RA, Anderson DM, Gough GW, Stanley MA. Cell-mediated immune responses to COPV early proteins. Virology 2006; 356: 23-34.
58. Nicholls PK, Moore PF, Anderson DM etal. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283: 31-39.
59. Coleman N, Birley HD, Renton AM etal. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-774.
60. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009; 384: 410-414.
61. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999; 6: 494-498.
62. Nakagawa M, Stites DP, Farhat S etal. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175: 927-931.
63. Nakagawa M, Stites DP, Patel S etal. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182: 595-598.
64. Woo YL, van den Hende M, Sterling JC etal. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer 2010; 126: 133-141.
65. de Jong A, van Poelgeest MI, van der Hulst JM etal. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-5455.
66. Welters MJ, van der Logt P, van den Eeden SJ etal. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118: 950-956.
67. van Poelgeest MI, van Seters M, van Beurden M etal. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11: 5273-5280.
68. Seresini S, Origoni M, Lillo F etal. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol 2007; 179: 7176-7183.
69. de Jong A, van der Burg SH, Kwappenberg KM etal. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-479.
70. Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010; 59: 799-803.
71. Peng S, Trimble C, Wu L etal. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007; 13: 2479-2487.
72. Visser J, Nijman HW, Hoogenboom BN etal. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 2007; 150: 199-209.
73. Molling JW, de Gruijl TD, Glim J etal. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 2007; 121: 1749-1755.
74. van der Burg SH, Piersma SJ, de Jong A etal. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A 2007; 104: 12087-12092.
75. Hessol NA, Holly EA, Efird JT etal. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23: 59-70.
76. Crum-Cianflone NF, Hullsiek KH, Marconi VC etal. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24: 535-543.
77. Kobayashi A, Greenblatt RM, Anastos K etal. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004; 64: 6766-6774.
78. Kobayashi A, Darragh T, Herndier B etal. Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol 2002; 160: 151-164.
79. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185: 251-257.
80. Palefsky JM, Giuliano AR, Goldstone S etal. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. N Engl J Med 2011; 365: 1576-1585.
81. Kreimer AR, Gonzalez P, Katki HA etal. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011; 12: 862-870.
82. Wilkin T, Lee JY, Lensing SY etal. Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men. J Infect Dis 2010; 202: 1246-1253.
83. CDC. Recommended adult immunization schedule - United States, 2012. MMWR 2012; 61: 1-7.
84. Kenter GG, Welters MJ, Valentijn AR etal. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-1847.
85. Welters MJ, Kenter GG, de Vos van Steenwijk PJ etal. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107: 11895-11899.
86. Simpson S, Turner R. Four decades of anal cancer in Tasmania, Australia: what do the case data tell us? Sex Health 2012; 9: 213-219.
87. Simpson JA, Scholefield JH. Diagnosis and management of anal intraepithelial neoplasia and anal cancer. BMJ 2011; 343: d6818.
88. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. Dis Colon Rectum 1997; 40: 919-928.
89. Darragh TM, Winkler B. Anal cancer and cervical cancer screening: key differences. Cancer Cytopathol 2011; 119: 5-19.
90. Darragh TM, Jay N, Tupkelewicz BA, Hogeboom CJ, Holly EA, Palefsky JM. Comparison of conventional cytologic smears and ThinPrep preparations from the anal canal. Acta Cytol 1997; 41: 1167-1170.
91. Solomon D, Davey D, Kurman R etal. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
92. Roberts JM, Ekman D. The reporting of anal cytology and histology samples: establishing terminology and criteria. Sex Health 2012; 9: 562-567.
93. Cachay ER, Agmas W, Mathews WC. Relative accuracy of cervical and anal cytology for detection of high grade lesions by colposcope guided biopsy: a cut-point meta-analytic comparison. PLoS ONE 2012; 7: e38956.
94. WHO. Human papillomavirus laboratory manual. First ed.; 2009.
95. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010; 14 (iii-iv, ix-x): 1-101.
96. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281: 1822-1829.
97. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic infections in HIV-infected adults and adolescents. MMWR 2009; 58: 68-75.
98. European AIDS Clinical Society. EACS guidelines. Version 6 ed, November 2012.
99. New York State Department of Health AIDS Institute. Anal Dysplasia and Cancer. New York, Neoplastic Complications of HIV Infection, 2007.
100. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis 2006; 43: 223-233.
101. Goldstone RN, Goldstone AB, Russ J, Goldstone SE. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum 2011; 54: 1284-1292.
102. Marks DK, Goldstone SE. Electrocautery ablation of high-grade anal squamous intraepithelial lesions in HIV-negative and HIV-positive men who have sex with men. J Acquir Immune Defic Syndr 2012; 59: 259-265.
103. Steele SR, Varma MG, Melton GB etal. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2012; 55: 735-749.
104. Wright TC, Jr, Massad LS, Dunton CJ etal. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197: 340-345.
105. Macaya A, Munoz-Santos C. Balaguer A and Barbera MJ. Interventions for anal canal intraepithelial neoplasia. Cochrane Database Syst Rev 2012; (12)CD009244.
106. Fox PA, Nathan M, Francis N etal. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS 2010; 24: 2331-2335.
107. Glynne-Jones R, Northover JM, Cervantes A. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v87-v92.
108. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys 2009; 75: 143-149.
109. Fraunholz I, Rabeneck D, Gerstein J etal. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 2011; 98: 99-104.
110. Frazer IH, Medley G, Crapper RM, Brown TC, Mackay IR. Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men. Lancet 1986; 2: 657-660.
111. National Health and Medical Research Council. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities. Australia 2006.
112. Hou JY, Smotkin D, Grossberg R etal. High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr 2012; 60: 169-172.
113. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003; 12: 638-642.